T2 Biosystems, Inc. Stock News

T2 Biosystems, Inc. (NASDAQ:TTOO ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Trip Taylor - Investor Relations John Sperzel - Chairman & Chief Executive Officer John Sprague - Chief Financial Officer Conference Call Participants Yi Chen - H.C. Wainwright Operator Greetings.

LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2024 and business updates after market close on Thursday, November 14, 2024.

T2 Biosystems, Inc. (NASDAQ:TTOO ) Business Update Conference Call October 10, 2024 4:30 PM ET Company Participants Trip Taylor - IR John Sperzel - Chairman and CEO Conference Call Participants Eduardo Martinez - H.C. Wainwright Operator Good day, everyone.

LEXINGTON, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will host a business update call to provide additional details on recent developments after market close at 4:30pm ET on Thursday October 10, 2024. On the call management also plans to address ...

LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered into a multi-year exclusive U.S. agreement with Cardinal Health (NYSE: CAH),. Under the agreement, Cardinal Health will have exclusive rights to sell T2 Biosystems'...

LEXINGTON, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has successfully defended against an opposition filed against a key patent for its direct-from-whole blood detection method in the European Union.

LEXINGTON, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming H.C. Wainwright 26th Annual Global Investment Conference.

LEXINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in two upcoming investor conferences in August 2024: